STRATA Skin Sciences Inc (SSKN) - Total Liabilities
Based on the latest financial reports, STRATA Skin Sciences Inc (SSKN) has total liabilities worth $29.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore STRATA Skin Sciences Inc (SSKN) cash conversion ratio to assess how effectively this company generates cash.
STRATA Skin Sciences Inc - Total Liabilities Trend (2002–2024)
This chart illustrates how STRATA Skin Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. Check STRATA Skin Sciences Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
STRATA Skin Sciences Inc Competitors by Total Liabilities
The table below lists competitors of STRATA Skin Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HCW Biologics Inc
NASDAQ:HCWB
|
USA | $27.55 Million |
|
Iofina plc
LSE:IOF
|
UK | GBX19.91 Million |
|
The Pebble Group PLC
LSE:PEBB
|
UK | GBX37.86 Million |
|
Wynnstay Group Plc
LSE:WYN
|
UK | GBX87.69 Million |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
Israel | ILA5.57 Million |
|
Nuwellis Inc
NASDAQ:NUWE
|
USA | $4.07 Million |
|
FINEQIA INTERN. INC. O.N.
F:FNQA
|
Germany | €55.02 Million |
Liability Composition Analysis (2002–2024)
This chart breaks down STRATA Skin Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see STRATA Skin Sciences Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 22.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STRATA Skin Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STRATA Skin Sciences Inc (2002–2024)
The table below shows the annual total liabilities of STRATA Skin Sciences Inc from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.18 Million | +6.33% |
| 2023-12-31 | $29.33 Million | -3.66% |
| 2022-12-31 | $30.44 Million | +43.73% |
| 2021-12-31 | $21.18 Million | +1.40% |
| 2020-12-31 | $20.89 Million | +11.75% |
| 2019-12-31 | $18.69 Million | +14.95% |
| 2018-12-31 | $16.26 Million | -0.78% |
| 2017-12-31 | $16.39 Million | -42.45% |
| 2016-12-31 | $28.47 Million | -19.30% |
| 2015-12-31 | $35.28 Million | +352.72% |
| 2014-12-31 | $7.79 Million | +33.55% |
| 2013-12-31 | $5.84 Million | +77.14% |
| 2012-12-31 | $3.29 Million | +107.74% |
| 2011-12-31 | $1.59 Million | -11.42% |
| 2010-12-31 | $1.79 Million | -1.15% |
| 2009-12-31 | $1.81 Million | +18.36% |
| 2008-12-31 | $1.53 Million | +14.50% |
| 2007-12-31 | $1.34 Million | +15.03% |
| 2006-12-31 | $1.16 Million | +26.78% |
| 2005-12-31 | $916.34K | -91.39% |
| 2004-12-31 | $10.65 Million | +1537.88% |
| 2003-12-31 | $650.00K | -87.00% |
| 2002-12-31 | $5.00 Million | -- |
About STRATA Skin Sciences Inc
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company offers XTRAC exc… Read more